ISTA Pharmaceuticals (ISTA -5.3%) trades lower after reporting mixed results from its eye drug...

|By:, SA News Editor

ISTA Pharmaceuticals (ISTA -5.3%) trades lower after reporting mixed results from its eye drug trials. Phase 3 studies to evaluate the short-term safety and efficacy of its drug Remura, a treatment for dry eye disease, showed it was effective but not statistically better than the placebo.